Opportunity Information: Apply for PA 09 250
Apply for PA 09 250
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (STTR R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Aug 12, 2009 and posted on Aug 12, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (PA-09-250) is a National Institutes of Health (NIH) funding opportunity that supports Small Business Technology Transfer (STTR) projects aimed at understanding and controlling how stem and progenitor cells become specialized cell types relevant to cardiovascular, pulmonary, and hematologic diseases. The program is centered on the practical challenge that limits many regenerative medicine approaches: reliably directing embryonic or adult stem/progenitor cells into specific, functional lineages. NIH is looking for projects that identify the key factors, signals, and biological mechanisms that govern differentiation, whether those processes are studied in vitro (for example, in culture systems that produce transplantable cells) or in vivo (for example, within the tissue environment where cells mature and integrate). A notable feature of this announcement is that it explicitly welcomes technology-focused research that may not be strictly hypothesis-driven, reflecting an intent to spur tool building, platform development, and other enabling advances that can accelerate the field.
The long-term objective is translation into clinically useful methods that generate replacement cells for therapy. These replacement cells could be manufactured outside the body and then delivered to patients, or they could be produced by directing differentiation inside the body within a target tissue or organ. In practice, this means the FOA is meant to help bridge early mechanistic insights and engineering advances toward tangible cell-based therapy pipelines for heart, lung, and blood conditions, including the ability to produce the right cell type, at the right maturity, with consistent function and safety.
The funding mechanism is the STTR R41/R42 pathway, which supports Phase I, Phase II, and Fast Track applications. Phase I typically emphasizes feasibility and proof of concept, while Phase II supports more extensive development and validation toward commercialization and downstream clinical use. As an STTR opportunity, it is structured for small business concerns (SBCs) working in formal collaboration with a research institution partner, aligning with the program goal of moving innovations from academic discovery into commercially viable therapeutic and enabling technologies. The announcement also notes that it runs in parallel with other NIH opportunities of the same scientific scope: an SBIR version (R43/R44; PA-09-249) and an Exploratory/Developmental grant version (R21; PA-09-248). This parallel structure signals that NIH wanted similar science pursued through multiple applicant types and development stages, from exploratory studies to small business-led commercialization efforts.
In terms of topic alignment and NIH program areas, the FOA is categorized under health research and tied to CFDA numbers 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research). There is no cost sharing or matching requirement, which lowers the barrier for small businesses that may not have substantial non-federal capital. The award ceiling listed is $250,000, and awards are explicitly contingent on the availability of funds and the receipt of a sufficient number of high-quality, meritorious applications. NIH also makes clear that the actual number and size of awards depend on the quality, duration, and budgets of the applications submitted rather than a guaranteed set-aside count.
Administratively, the opportunity was posted and created on August 12, 2009, with an original closing date of September 7, 2012, and it was archived on October 8, 2012. Eligibility is limited to small businesses, consistent with the STTR program’s mission of stimulating technological innovation and facilitating commercialization through small business-academic collaborations. The agency contact listed for access or technical problems is the NIH Office of Extramural Research (OER) Webmaster (FBOWebmaster@OD.NIH.GOV), and the full announcement was hosted on the NIH grants guide page associated with PA-09-250.
Frequently Asked Questions (FAQs)
What is the grant opportunity "Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (PA-09-250)"?
It is a National Institutes of Health (NIH) funding opportunity that supports Small Business Technology Transfer (STTR) projects focused on understanding and controlling how stem and progenitor cells differentiate into specialized, functional cell types relevant to cardiovascular, pulmonary, and hematologic diseases.
What is the main scientific focus of PA-09-250?
The program targets the practical barrier that limits many regenerative medicine approaches: reliably directing embryonic or adult stem/progenitor cells into specific, functional lineages. Projects are expected to identify key factors, signals, and biological mechanisms that govern differentiation.
Which disease areas does this opportunity cover?
The scope includes heart, lung, and blood diseases. It is tied to NIH program areas reflected by CFDA numbers 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research).
What kinds of studies are encouraged: in vitro, in vivo, or both?
Both are included. NIH is interested in work performed in vitro (for example, culture systems that produce transplantable cells) as well as in vivo (for example, studying differentiation within tissue environments where cells mature and integrate).
Does the FOA allow technology-focused work that is not strictly hypothesis-driven?
Yes. A notable feature is that it explicitly welcomes technology-focused research that may not be strictly hypothesis-driven, with the intent to spur tool building, platform development, and other enabling advances.
What is the long-term objective of the program?
The long-term objective is translation into clinically useful methods that generate replacement cells for therapy for heart, lung, and blood conditions, including consistent function and safety.
What are the intended therapy pathways supported by this FOA?
The FOA supports approaches where replacement cells are manufactured outside the body and delivered to patients, as well as approaches that aim to direct differentiation inside the body within a target tissue or organ.
What funding mechanism is used for PA-09-250?
The opportunity uses the STTR R41/R42 mechanism, which supports Phase I, Phase II, and Fast Track applications.
What is the difference between Phase I and Phase II under this STTR opportunity?
Phase I typically emphasizes feasibility and proof of concept. Phase II supports more extensive development and validation toward commercialization and downstream clinical use.
Does PA-09-250 support Fast Track applications?
Yes. The R41/R42 pathway for this announcement supports Phase I, Phase II, and Fast Track submissions.
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with the STTR program structure.
Is a collaboration required under this opportunity?
Yes. As an STTR opportunity, it is structured for small business concerns (SBCs) working in formal collaboration with a research institution partner, aligning with the goal of moving innovations from academic discovery into commercially viable technologies.
Are there related NIH opportunities with a similar scientific scope?
Yes. The announcement notes parallel NIH opportunities covering the same scientific scope: an SBIR version (R43/R44; PA-09-249) and an Exploratory/Developmental grant version (R21; PA-09-248).
What is the award ceiling listed for this opportunity?
The listed award ceiling is $250,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Are awards guaranteed if an application is submitted?
No. Awards are contingent on the availability of funds and on receiving a sufficient number of high-quality, meritorious applications. NIH also states that the number and size of awards depend on application quality, duration, and budgets rather than a guaranteed set-aside.
When was this opportunity posted and what is its current status?
It was posted/created on August 12, 2009. It had an original closing date of September 7, 2012, and it was archived on October 8, 2012.
Where was the full announcement hosted?
The full announcement was hosted on the NIH Grants Guide page associated with PA-09-250.
Who should be contacted for access or technical problems related to this announcement?
The agency contact listed for access or technical problems is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Vocational Rehabilitation Services Projects for American Indians With Disabilities Competition for the Vocational Rehabilitation Services Projects for American Indians With Disabilities Program CFDA 84.250A
Previous opportunity: Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, and Blood Diseases (SBIR R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 250
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 250) also looked into and applied for these:
| Funding Opportunity |
|---|
| Transforming Primary Care Practice (R18) Apply for RFA HS 10 002 Funding Number: RFA HS 10 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $300,000 |
| NEI Research Grant for Secondary Data Analysis (R21) Apply for PAR 09 252 Funding Number: PAR 09 252 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research to Understand and Inform Interventions that Promote the Research Careers of Students in Biomedical and Behavioral Sciences (R01) Apply for RFA GM 10 008 Funding Number: RFA GM 10 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Non Human Primate Heart/Lung Transplantation Tolerance (U01, U19) Apply for RFA AI 09 041 Funding Number: RFA AI 09 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) for Year 2009 (P50) Apply for PAR 09 254 Funding Number: PAR 09 254 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Erythropoiesis Components and Mechanisms (R01) Apply for PA 09 255 Funding Number: PA 09 255 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) Apply for PAR 09 256 Funding Number: PAR 09 256 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Rehabilitation in District Environs (STRIDE) Apply for RFA 367 09 000001 Funding Number: RFA 367 09 000001 Agency: Nepal USAID Kathmandu Category: Health Funding Amount: $1,200,000 |
| 2010 NIH Directors Pioneer Award Program (DP1) Apply for RFA RM 09 010 Funding Number: RFA RM 09 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Network Infrastructure Support for Emerging Behavioral and Social Research Areas in Aging (R24) Apply for PAR 09 233 Funding Number: PAR 09 233 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Healthy Aging through Behavioral Economic Analyses of Situations (R01) Apply for RFA AG 10 008 Funding Number: RFA AG 10 008 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| Traumatic Brain Injury Protection and Advocacy Apply for HRSA 10 145 Funding Number: HRSA 10 145 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effects of Gene Social Environment Interplay on Health and Behavior in Later Life (R01) Apply for RFA AG 10 006 Funding Number: RFA AG 10 006 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Grant Program for Large or Recurring Conferences (R13) Apply for PAR 09 257 Funding Number: PAR 09 257 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Centers for Medical Countermeasures Against Radiation (U19) Apply for RFA AI 09 036 Funding Number: RFA AI 09 036 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| NIGMS National Centers for Systems Biology (P50) Apply for PAR 09 258 Funding Number: PAR 09 258 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 11 001 Funding Number: RFA GM 11 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Small Grant Program for Conference Support (R13) Apply for PA 09 231 Funding Number: PA 09 231 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| USAID/Nigerias Proposed Malaria Project Invitation for Comments on Draft PD Apply for 620 09 020 Funding Number: 620 09 020 Agency: Nigeria USAID Abuja Category: Health Funding Amount: $110,000,000 |
| 2010 NIH Directors New Innovator Award Program (DP2) Apply for RFA RM 09 011 Funding Number: RFA RM 09 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 250", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.